NCT00739453 2024-11-20
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma Inc
Phase 1 Completed
Clinical Trials
13 trialsNCT02723578 2020-01-13
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Yonsei University
Phase 2 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00265824 2015-12-11
DREAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT01229813 2015-04-13
ACT2
Lund University Hospital
Phase 3 Completed
NCT01135498 2015-02-06
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00049101 2013-06-24
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00598156 2013-04-22
ACT
Lund University Hospital
Phase 3 Completed
NCT00118261 2012-09-03
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00603356 2011-09-27
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT00123851 2009-04-28
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00116506 2007-12-21
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047762 2005-06-24
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Genentech, Inc.
Phase 1 Completed